Meeting
2013 ASCO Annual Meeting
Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification).
Authors
Silvia Marsoni
Clinical Trial Coordination Unit - IRCC Istitute for Cancer Research and Treatment at Candiolo, Candiolo, Italy
Silvia Marsoni , Andrea Bertotti , Andrea Sartore-Bianchi , Francesco Leone , Sara Lonardi , Fortunato Ciardiello , Carmine Pinto , Massimo Aglietta , Vittorina Zagonel , Marcello Gambacorta , Walter Franco Grigioni , Massimo Rugge , Mauro Risio , Cosimo Martino , Emanuele Valtorta , Alberto Bardelli , Livio Trusolino , Paolo M. Comoglio , Salvatore Siena
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
2012-002128-33
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS3648)
DOI
10.1200/jco.2013.31.15_suppl.tps3648
Abstract #
TPS3648
Poster Bd #
15B
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial.
First Author: Salvatore Siena
Poster
2017 ASCO Annual Meeting
A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+ metastatic colorectal cancer (mCRC)(MOUNTAINEER).
First Author: John H. Strickler
Poster
2022 ASCO Annual Meeting
NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or N plus cetuximab (C) in patients (pts) with "quadruple wild-type" metastatic colorectal cancer (mCRC) based on HER2 status.
First Author: Samuel A. Jacobs
Poster
2021 Gastrointestinal Cancers Symposium
MOUNTAINEER: open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).
First Author: John H. Strickler